The mitochondrial energy score (TSS) protocol developed by the group Myhill, is marketed as a diagnostic test for chronic fatigue syndrome / myalgic encephalomyelitis (CFS / ME). This study evaluated the reliability and reproducibility of the test, currently provided by private clinics, to assess its potential to be developed as an NHS accredited laboratory test.
We reproduced the ESM protocol using neutrophils and peripheral blood mononuclear cells (PBMC) of patients with CFS / ME (10) and healthy controls (13). The protocol was then repeated in PBMCs and neutrophils from healthy controls to investigate the effect of the delayed sample processing time used by the group Myhill.
Experiments using the established protocol showed no difference between patients CFS / ME and healthy controls in one of the components of the MES (p ≥ 0.059). Delaying treatment blood samples within 24 hours (and in the period of 72 hours cited by Myhill group) significantly altered number of parameters used to calculate the MES in both neutrophils and PBMCs.
The MES test was not required reliability and reproducibility of a diagnostic test and should therefore not be proposed as a diagnostic test for CFS / ME. The differences observed by Myhill group may be reduced to differences in processing time between sample cohorts.
Advances in ME/CFS: Past, Present, and Future.
The precursor of what is now known as myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) has been described by the Public Health Service of the United States in 1934. At present, we do not yet know the cause and / or how to detect by routine clinical laboratory tests.
Accordingly, the nature of the disease ME / CFS has been overlooked and the disease was wrongly stigmatized by such a psychosomatic or somatoform illness. These misperceptions of the disease have led to the exploration of insufficient research of the disease and a minimum of care for patients absent.
A report by the Institute of Medicine in 2015 declared the disease ME / CFS a disease that affects up to 2.5 million Americans and rebuked the US government for doing little to research the disease and support patients .
Clinicians currently treating the disease state be more devastating than HIV / AIDS. A comparison of the stories of the two diseases, a review of the current status of the two diseases, and a list of accomplishments that would be required for ME / CFS to achieve the same level of treatment and currently care of patients with HIV / AIDS is provided.